Compugen Ltd. (NASDAQ:CGEN) will be discussing 3Q20 financial results with the investment community.on 5th November 2020 at 8:30 AM eastern time.
Those interested in listening to the conference call live via the Internet can visit www.cgen.com
Earnings Expectation
Compugen Ltd. is expected to report third quarter earnings results, before market open, on Thursday 5th November 2020. Analysts polled by Thomson Reuters anticipate third quarter loss of $ 0.09 per share. Looking ahead, the full year loss are expected at $ 0.36 per share.
Compugen Ltd., a therapeutic discovery company, engages in the research, development, and commercialization of therapeutic and product candidates in Israel, the United States, and Europe. The companys therapeutic pipeline consists of immuno-oncology programs against novel drug targets, including T cell immune checkpoints and other early-stage immuno-oncology programs focusing on myeloid target. Its product pipeline consists of COM701, a therapeutic antibody that is in phase I clinical trials for PVRIG; BAY 1905254, a therapeutic antibody that is in phase I clinical trials for ILDR2; and COM902, a therapeutic immuno-oncology antibody for TIGIT program.
